Conditions: Multiple Myeloma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 4
Healthy volunteers: no

Brief summary:
This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses closer together (before the myeloma comes back or gets worse), subjects in this study will have better outcomes.

Detailed description:
This study has the following goals:

* To find out how many subjects treated with high dose DTPACE (Dexamethasone, Thalidomide, CisPlatin, Adriamycin, Cyclophosphamide, and Etoposide. (HD DTPACE) on this protocol will have a complete response or near complete response that lasts for 6 months or longer.
* In subjects achieving a response, to find out how long the response will last.
* To learn more about the side effects of this treatment.

Up to 75 subjects, male or female, age 18 and older, regardless of race or ethnicity, will participate in this study at the University of Arkansas for Medical Sciences (UAMS) only.

The treatment in this study is divided into 3 parts

* High dose DTPACE and stem cell collection if you do not already have sufficient stem cells stored.
* High dose DTPACE and stem cell re-infusion.
* Velcade, Thalidomide, Dexamethasone (sometimes known as VTD) Maintenance therapy.

Arms:
arm 1: DTPACE

Interventions: intervention 1: DTPACE
Intervention descriptions: intervention 1: * Dexamethasone 200 mg Intravenous Infusion "Piggy-Back" (IVPB) Days 1-7
* Thalidomide 200 mg by mouth (PO) Days 1-7
* Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)
* Adriamycin 15 mg/m2 Days 1-4
* Cyclophosphamide 600 mg/m2 Days 1-4
* Etoposide 60 mg/m2 Days 1-4

Protocol document: